Skip to main content
News Icon

News categories: Publication

Regulation of Innate Immune Responses by Platelets

Platelets have been extensively studied in the context of coagulation and their hemostatic imbalance can lead to conditions as atherosclerotic plaques and thrombosis. Nevertheless, the knowledge regarding the regulation of immune cell types by platelets has been growing exponentially in the past years. Among these biological systems, the innate immunity is remarkably affected by the crosstalk with platelets. This interaction comes from the formation of platelet-leukocyte aggregates, signaling by direct contact or by stimulation of immune cells by soluble factors and microparticles secreted by platelets. These blood components can sense and react danger signals, guiding leukocytes to injury sites and providing a scaffold for the formation of extracellular traps for microbial clearance. Using different mechanisms, platelets have the task to regulate the release of cytokines and chemokines upon sterile or infectious damage, modulate the expression of cell markers and control cell death and survival. Therefore, platelets are more than clotting agents, but critical players within the immune equilibrium for the host. Here we present an understanding about how platelets modulate innate immune cells, as well as a summary of the outcome of this interaction, an important step for therapeutic opportunities and future research on infectious and autoimmune diseases.


Publication

https://www.immunosensation.de/research/publications/pubmed/regulation-of-innate-immune-responses-by-platelets.html


Contact

Prof. Bernardo Franklin

Institute of Innate Immunity

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview